Jessica Fye
Stock Analyst at JP Morgan
(4.41)
# 322
Out of 5,054 analysts
220
Total ratings
59.42%
Success rate
14.56%
Average return
Main Sectors:
Stocks Rated by Jessica Fye
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| DNLI Denali Therapeutics | Maintains: Overweight | $24 → $26 | $15.60 | +66.67% | 6 | Nov 4, 2025 | |
| STOK Stoke Therapeutics | Maintains: Neutral | $15 → $25 | $22.37 | +11.76% | 5 | Nov 3, 2025 | |
| NVCR NovoCure | Maintains: Neutral | $25 → $23 | $11.27 | +104.08% | 5 | Oct 27, 2025 | |
| JAZZ Jazz Pharmaceuticals | Maintains: Overweight | $204 → $199 | $133.19 | +49.41% | 5 | Oct 27, 2025 | |
| HALO Halozyme Therapeutics | Maintains: Neutral | $63 → $65 | $68.01 | -4.43% | 15 | Oct 27, 2025 | |
| MRNA Moderna | Maintains: Underweight | $26 → $25 | $24.76 | +0.97% | 14 | Oct 23, 2025 | |
| BNTX BioNTech SE | Maintains: Neutral | $121 → $120 | $105.07 | +14.21% | 14 | Oct 23, 2025 | |
| ALNY Alnylam Pharmaceuticals | Maintains: Overweight | $475 → $473 | $441.70 | +7.09% | 9 | Oct 13, 2025 | |
| LEGN Legend Biotech | Maintains: Overweight | $78 → $76 | $31.59 | +140.58% | 4 | Oct 9, 2025 | |
| INCY Incyte | Maintains: Neutral | $73 → $89 | $105.98 | -16.02% | 9 | Oct 9, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $116 → $119 | $52.67 | +125.94% | 5 | Oct 9, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $260 → $264 | $196.01 | +34.69% | 16 | Oct 9, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $517 → $530 | $421.20 | +25.83% | 10 | Oct 8, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $345 → $385 | $329.20 | +16.95% | 4 | Oct 8, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Overweight | $49 → $80 | $69.54 | +15.04% | 7 | Oct 8, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $53 → $52 | $41.46 | +25.42% | 6 | Sep 24, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $53 → $77 | $69.72 | +10.44% | 4 | Sep 12, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Neutral | $34 → $35 | $32.65 | +7.20% | 7 | Sep 9, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $111 → $135 | $191.92 | -29.66% | 9 | Aug 20, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $350 → $330 | $453.93 | -27.30% | 17 | Jul 8, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $10 → $13 | $7.20 | +80.56% | 6 | May 6, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $54 → $50 | $35.00 | +42.86% | 5 | Apr 14, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Overweight | $30 | $24.49 | +22.50% | 1 | Oct 8, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reinstates: Underweight | n/a | $57.97 | - | 7 | Nov 20, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reinstates: Underweight | n/a | $10.99 | - | 2 | Nov 20, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reinstates: Neutral | n/a | $2.88 | - | 9 | Nov 20, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reinstates: Underweight | n/a | $15.85 | - | 6 | Nov 20, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Underweight | n/a | $1.27 | - | 2 | Aug 20, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Overweight | $22 | $1.61 | +1,266.46% | 1 | Apr 19, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Neutral | $7 | $1.42 | +392.96% | 2 | Jan 29, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Underweight | n/a | $8.61 | - | 4 | Mar 11, 2019 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Underweight | n/a | $7.11 | - | 3 | Feb 28, 2019 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Neutral | n/a | $11.53 | - | 1 | Feb 8, 2018 |
Denali Therapeutics
Nov 4, 2025
Maintains: Overweight
Price Target: $24 → $26
Current: $15.60
Upside: +66.67%
Stoke Therapeutics
Nov 3, 2025
Maintains: Neutral
Price Target: $15 → $25
Current: $22.37
Upside: +11.76%
NovoCure
Oct 27, 2025
Maintains: Neutral
Price Target: $25 → $23
Current: $11.27
Upside: +104.08%
Jazz Pharmaceuticals
Oct 27, 2025
Maintains: Overweight
Price Target: $204 → $199
Current: $133.19
Upside: +49.41%
Halozyme Therapeutics
Oct 27, 2025
Maintains: Neutral
Price Target: $63 → $65
Current: $68.01
Upside: -4.43%
Moderna
Oct 23, 2025
Maintains: Underweight
Price Target: $26 → $25
Current: $24.76
Upside: +0.97%
BioNTech SE
Oct 23, 2025
Maintains: Neutral
Price Target: $121 → $120
Current: $105.07
Upside: +14.21%
Alnylam Pharmaceuticals
Oct 13, 2025
Maintains: Overweight
Price Target: $475 → $473
Current: $441.70
Upside: +7.09%
Legend Biotech
Oct 9, 2025
Maintains: Overweight
Price Target: $78 → $76
Current: $31.59
Upside: +140.58%
Incyte
Oct 9, 2025
Maintains: Neutral
Price Target: $73 → $89
Current: $105.98
Upside: -16.02%
Oct 9, 2025
Maintains: Overweight
Price Target: $116 → $119
Current: $52.67
Upside: +125.94%
Oct 9, 2025
Maintains: Overweight
Price Target: $260 → $264
Current: $196.01
Upside: +34.69%
Oct 8, 2025
Maintains: Overweight
Price Target: $517 → $530
Current: $421.20
Upside: +25.83%
Oct 8, 2025
Maintains: Overweight
Price Target: $345 → $385
Current: $329.20
Upside: +16.95%
Oct 8, 2025
Upgrades: Overweight
Price Target: $49 → $80
Current: $69.54
Upside: +15.04%
Sep 24, 2025
Maintains: Overweight
Price Target: $53 → $52
Current: $41.46
Upside: +25.42%
Sep 12, 2025
Maintains: Overweight
Price Target: $53 → $77
Current: $69.72
Upside: +10.44%
Sep 9, 2025
Maintains: Neutral
Price Target: $34 → $35
Current: $32.65
Upside: +7.20%
Aug 20, 2025
Maintains: Overweight
Price Target: $111 → $135
Current: $191.92
Upside: -29.66%
Jul 8, 2025
Maintains: Overweight
Price Target: $350 → $330
Current: $453.93
Upside: -27.30%
May 6, 2025
Maintains: Overweight
Price Target: $10 → $13
Current: $7.20
Upside: +80.56%
Apr 14, 2025
Maintains: Overweight
Price Target: $54 → $50
Current: $35.00
Upside: +42.86%
Oct 8, 2024
Initiates: Overweight
Price Target: $30
Current: $24.49
Upside: +22.50%
Nov 20, 2023
Reinstates: Underweight
Price Target: n/a
Current: $57.97
Upside: -
Nov 20, 2023
Reinstates: Underweight
Price Target: n/a
Current: $10.99
Upside: -
Nov 20, 2023
Reinstates: Neutral
Price Target: n/a
Current: $2.88
Upside: -
Nov 20, 2023
Reinstates: Underweight
Price Target: n/a
Current: $15.85
Upside: -
Aug 20, 2021
Downgrades: Underweight
Price Target: n/a
Current: $1.27
Upside: -
Apr 19, 2021
Initiates: Overweight
Price Target: $22
Current: $1.61
Upside: +1,266.46%
Jan 29, 2021
Upgrades: Neutral
Price Target: $7
Current: $1.42
Upside: +392.96%
Mar 11, 2019
Downgrades: Underweight
Price Target: n/a
Current: $8.61
Upside: -
Feb 28, 2019
Downgrades: Underweight
Price Target: n/a
Current: $7.11
Upside: -
Feb 8, 2018
Downgrades: Neutral
Price Target: n/a
Current: $11.53
Upside: -